Evidence map›Paper›PMID 36842755›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2023

Emergent Omicron BR.2.1 sublineage of SARS-CoV-2 in New South Wales, Australia: a subvariant with high fitness but without increased disease severity.

Annaleise R Howard-Jones, Alicia Arnott, Jenny Draper, Mailie Gall, Sally Ellis, Kelsi Marris, Christine Selvey, Kerri Basile, Dominic E Dwyer, Vitali Sintchenko and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Annaleise R Howard-JonesCentre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology-Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Australia; Sydney Institute for Infectious Diseases, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Alicia ArnottSydney Institute for Infectious Diseases, Faculty of Medicine and Health, University of Sydney, Sydney, Australia; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Westmead, Australia.
Jenny DraperCentre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology-Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Australia; Sydney Institute for Infectious Diseases, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Mailie GallCentre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology-Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Australia; Sydney Institute for Infectious Diseases, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Sally EllisNew South Wales Ministry of Health, St Leonards, Australia.
Kelsi MarrisNew South Wales Ministry of Health, St Leonards, Australia.
Christine SelveyNew South Wales Ministry of Health, St Leonards, Australia.
Kerri BasileCentre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology-Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Australia; Sydney Institute for Infectious Diseases, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Dominic E DwyerCentre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology-Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Australia; Sydney Institute for Infectious Diseases, Faculty of Medicine and Health, University of Sydney, Sydney, Australia; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Westmead, Australia.
Vitali SintchenkoCentre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology-Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Australia; Sydney Institute for Infectious Diseases, Faculty of Medicine and Health, University of Sydney, Sydney, Australia; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Westmead, Australia.
Jen KokCentre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology-Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Australia; Sydney Institute for Infectious Diseases, Faculty of Medicine and Health, University of Sydney, Sydney, Australia; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Westmead, Australia. Electronic address: jen.kok@health.nsw.gov.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo describe the epidemiology and impact of Omicron BR.2.1, an emergent SARS-CoV-2 Omicron BA.2.75 sublineage displaying high fitness compared to other cocirculating subvariants in New South Wales, Australia.

methodsFrom September 01 to November 26, 2022, 4971 SARS-CoV-2 consensus genomes from unique patients were generated, and correlated with international travel and reinfection history, and admission to the intensive care unit.

resultsBR.2.1 became the predominant variant by late November, and was responsible for a significantly higher proportion of community-acquired cases during the study period (55.1% vs 38.4%, P < 0.001). Reinfections (defined as occurring between 6 and 24 weeks after a prior diagnosis of COVID-19) were significantly higher among BR.2.1 compared to non-BR.2.1 infected persons (17.0% vs 6.0%, P < 0.001). BR.2.1 cases were also significantly younger compared to non-BR.2.1 (median age 48 years (interquartile range [IQR] 32) vs 53 years (IQR 32), P = 0.004). The proportion of patients admitted to the intensive care unit with BR.2.1 was not significantly higher than other subvariants (2.3% vs 2.0%, P = 0.717).

conclusionHaving emerged locally within New South Wales, BR.2.1 caused a significant number of SARS-CoV-2 reinfections, but with disease severity comparable with other currently circulating lineages. Given its rapid rise in prevalence, BR.2.1 has the potential to become established internationally.

Indexed as

COVID-19SARS-CoV-2AdultAustraliaHumansNew South WalesOrganometallic CompoundsPatient AcuityReinfectioncarboxymethyl-dextran-A2-gadolinium-DOTAOrganometallic CompoundsCOVID-19Genomic surveillanceOmicronSARS-CoV-2Variants of concern

Identifiers

PMID36842755
PMCPMC9957655

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.